Search
Tirzepatide
go.drugbank.com/drugs/DB15171ApprovedInvestigational[L48766] On September 15, 2022, tirzepatide was also approved by the European Commission.[L44386]. On November 02, 2023, tirzepatide was also approved by the Health Canada [L52800] … [A246260] Its protein sequence was based on the sequence of endogenous GIP, and its pharmacological action on GLP-1 receptors is comparable to endogenous GIP; however, the long half-life of tirzepatide
Categories: Drugs Used in DiabetesProducts: Mounjaro 2.5 mg solution for injection in pre-filled pen, Mounjaro 5 mg solution for injection in pre-filled penMaribavir
go.drugbank.com/drugs/DB06234ApprovedInvestigational[L39327] The drug was also approved by Health Canada in September 2022 [L43262] and by European Commission in November 2022.[L44411] … [A242557] Maribavir is novel in that it instead targets the CMV pUL97 kinase, thereby providing an effective alternative treatment option in cases of resistant infections.
Selenium
go.drugbank.com/drugs/DB11135ApprovedInvestigationalVet approvedSelenium is a trace metal in the human body particularly important as a component of glutathione peroxidase, an important enzyme in the prevention of cellular damage by free radicals and reactive oxygen
Mixtures: Coen.q10w.vit.c and E Beta-car.se Cu Zn Mn, Ribotin-ECategories: Compounds used in a research, industrial, or household settingSodium fluoride
go.drugbank.com/drugs/DB09325ApprovedInvestigationalThe use of fluoride in dental practice began in the 1940s. … [L4894] Sodium fluoride's benefits on dental health were first observed in the 1930s, when individuals in communities with fluoridated drinking water showed less tooth decay than those without fluoridated
Mixtures: PREVENT 2 EN 1, E-Z CupsCategories: Compounds used in a research, industrial, or household settingTrastuzumab deruxtecan
go.drugbank.com/drugs/DB14962ApprovedInvestigational[A188988] Trastuzumab deruxtecan was developed by Daiichi Sankyo in collaboration with AstraZeneca and was first approved by the FDA in 2019.[L10842] … [L10842] It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes it from other members of its class.
Inclisiran
go.drugbank.com/drugs/DB14901ApprovedInvestigational[A225953,A225958] On December 11, 2020, the European Commission (EC) granted authorization for marketing inclisiran as the first and only approved siRNA for the treatment of adults with primary hypercholesterolemia … [L28178] Inclisiran was later approved by the FDA on December 22, 2021, for the treatment of heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease in adults
Categories: Compounds used in a research, industrial, or household settingProducts: LEQVIO SOLUTION FOR INJECTION IN PREFILLED SYRINGE 284 MG/1.5 ML, Sybrava 284mg/1.5ml Solution for Injection in Pre-filled SyringeElranatamab
go.drugbank.com/drugs/DB15395ApprovedInvestigational[L47820] Elranatamab was also approved by the European Commission on December 8, 2023.[L50437] … It is a humanized immunoglobulin 2-alanine kappa antibody derived from two monoclonal antibodies (mAbs), an anti-BCMA mAb and an anti-CD3 mAb,[A261060] each of which contributes one heavy chain and one
Efbemalenograstim alfa
go.drugbank.com/drugs/DB18704ApprovedInvestigationalThis approval was contingent on positive results observed in two pivotal Phase 3 Studies GC-627-04 and GC-627-05 in the US and Europe respectively.[L48887] … [A33650,A262172] On November 22, 2023, efbemalenograstim alfa was approved by the FDA under the brand name Ryzneuta for the treatment of chemotherapy-induced neutropenia in adult patients with non-myeloid
Inotuzumab ozogamicin
go.drugbank.com/drugs/DB05889ApprovedInvestigational[A20352] Inotuzumab ozogamicin was first approved by the European Commission in June 2017 for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). … Inotuzumab ozogamicin is an antibody-drug conjugate consisting of a humanized IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin
Tezepelumab
go.drugbank.com/drugs/DB15090ApprovedInvestigational[L39504] Tezepelumab was also approved by the European Commission on September 19, 2022.[L44712] … It was granted FDA approval on December 17, 2021, and is currently marketed under the trademark TEZSPIRE by Amgen/AstraZeneca.